Advertisement
Screener

Belite Bio, Inc (BLTE) Graph

BLTE Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2025-12-31: Research and development $45.38M; Selling, general and administrative $38.83M; Operating expenses $84.21M; Income tax $0.00.
  • 2024-12-31: Research and development $29.94M; Selling, general and administrative $10.06M; Operating expenses $40.00M; Income tax $6.00K.
  • 2023-12-31: Research and development $24.84M; Selling, general and administrative $6.82M; Operating expenses $31.67M; Income tax $9.00K.
  • 2022-12-31: Research and development $8.87M; Selling, general and administrative (m); Operating expenses $12.82M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 12 month

Period endResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$45.38M$38.83M$84.21M$0.00-$77.61M
2024-12-31$29.94M$10.06M$40.00M$6.00K-$36.14M
2023-12-31$24.84M$6.82M$31.67M$9.00K-$31.63M
2022-12-31$8.87M(m)$12.82M(m)-$12.65M
2021-12-31$7.42M(m)$9.80M(m)-$9.67M
2020-12-31$3.69M(m)$5.74M$1.00K-$5.75M